{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-078049","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.279805+00:00","generated_at":"2026-06-10T12:00:58.757363+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Relmada reports Phase 3 open-label data for REL-1017 in MDD: rapid, sustained symptom improvement","bullets":["In 204 de novo patients, mean MADRS total score improved 11.3 points at Day 7 and 22.5 points at Month 12.","Clinical response (≥50% MADRS improvement) achieved by 26.6% at Day 7 and 77.2% at Month 12.","Remission (MADRS ≤10) rates were 12.1% at Day 7 and 54.4% at Month 12.","Safety: ~3% discontinuation due to AEs; no new safety signals; common AEs were headache (4.4%), nausea (4.0%), dizziness (2.4%).","Functional impairment (SDS) improved ~50% by Month 6 in de novo patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-078049","json":"https://secwatch.observer/filing/0001213900-23-078049.json","markdown":"https://secwatch.observer/filing/0001213900-23-078049.md","text":"https://secwatch.observer/filing/0001213900-23-078049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/0001213900-23-078049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/ea185487-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T12:00:58.757363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}